Trial Profile
A Multi-Centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TYNERGY
- Sponsors Biogen
- 10 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), according to a Biogen Idec media release.
- 04 Aug 2012 Actual initiation date changed from 1 Apr 2009 to 13 March 2009 as reported by European Clinical Trials Database record.
- 28 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology.